Breaking News, Collaborations & Alliances

Sarepta and Dyno Therapeutics Will Develop Next-Gen Gene Therapy Vectors

Dyno’s proprietary CapsidMap platform opens up new ways to identify novel capsids

By: Contract Pharma

Contract Pharma Staff

Sarepta Therapeutics Inc. and Dyno Therapeutics Inc., have announced an agreement to develop next-generation Adeno-Associated Virus (AAV) vectors for muscle diseases, using Dyno’s CapsidMap platform.     Dyno’s proprietary CapsidMap platform opens up new ways to identify novel capsids – the cell-targeting protein shell of viral vectors – that could offer improved muscle targeting and immune-evading properties, in addition to advantages in packaging and manufacturing.   “Our agreement with Dyno p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters